Trial Profile

Phase II trial of reovirus as neoadjuvant therapy in patients with metastatic colorectal cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Sep 2025 According to an Oncolytics Biotech media release, based on the immune activation observed in REO 013 and the survival benefit seen in REO 022, the company plans to initiate an investigator-sponsored trial to further explore pelareorep's potential in KRAS-mutant metastatic colorectal cancer (mCRC).
08 Sep 2025 According to an Oncolytics Biotech media release, the company announced clinical and translational data highlights from three metastatic colorectal cancer (mCRC) studies - REO 022, GOBLET, and REO 013 , and plans to advance regulatory pathway discussions.
13 Jun 2012 Final results were published in the journal Science Translational Medicine, according to an Oncolytics Biotech media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com